Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

References

• Sung H , Ferlay J , Siegel RL , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2021;71(3):209–249.33538338
   PubMed Web of Science ®Google Scholar
• Siegel RL , Miller KD , Jemal A . Cancer statistics, 2020. CA Cancer J Clin . 2020;70(1):7–30.31912902
   PubMed Web of Science ®Google Scholar
• Siegel RL , Miller KD , Goding Sauer A , et al. Colorectal cancer statistics, 2020. CA Cancer J Clin . 2020;70(3):145–164.32133645
   PubMed Web of Science ®Google Scholar
• Ettrich TJ , Seufferlein T . Regorafenib. Recent Results Cancer Res . 2018;211:45–56.30069758
   PubMedGoogle Scholar
• Krishnamoorthy SK , Relias V , Sebastian S , Jayaraman V , Saif MW . Management of regorafenib-related toxicities: a review. Therap Adv Gastroenterol . 2015;8(5):285–297.
   PubMed Web of Science ®Google Scholar
• Grothey A , Cutsem EV , Sobrero A , et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet . 2013;381(9863):303–312.23177514
   PubMed Web of Science ®Google Scholar
• Li J , Qin S , Xu R , et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol . 2015;16(6):619–629.25981818
   PubMed Web of Science ®Google Scholar
• Demetri GD , Reichardt P , Kang Y-K , et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet . 2013;381(9863):295–302.23177515
   PubMed Web of Science ®Google Scholar
• Bruix J , Qin S , Merle P , et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet . 2017;389(10064):56–66.27932229
   PubMed Web of Science ®Google Scholar
• Han G , Meinhardt G , Schlief S , Fiala-Buskies S , Rutstein M , Wuchter-Czerwony C Integrated safety analysis from four phase 3 trials of regorafenib. Paper presented at: International Liver Cancer Association’s (ICLA) 11th Annual Conference; September 15–17, 2017; Seoul, South Korea.
   Google Scholar
• Sitlinger A , Zafar SY . Health-related quality of life: the impact on morbidity and mortality. Surg Oncol Clin N Am . 2018;27(4):675–684.30213412
   PubMed Web of Science ®Google Scholar
• Kluetz PG , Slagle A , Papadopoulos EJ , et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res . 2016;22(7):1553–1558.26758559
   PubMed Web of Science ®Google Scholar
• Chang J , Casali PG , Reichardt P , et al. Health-related quality of life (HRQoL) of patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib (REG) vs placebo (P) in the Phase III GRID trial. Paper presented at: The European Cancer Congress 2013; September 27-October 01, 2013; Amsterdam, The Netherlands.
   Google Scholar
• Chang J , Odom D , Radder C , et al. A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. J Clin Oncol . 2015;33(3_suppl):667.25605839
   PubMed Web of Science ®Google Scholar
• Charton E , Cuer B , Cottone F , et al. Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review. Qual Life Res . 2019.
   PubMed Web of Science ®Google Scholar
• Anota A , Hamidou Z , Paget-Bailly S , et al. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res . Jan . 2015;24(1):5–18.
   Google Scholar
• Osoba D , Rodrigues G , Myles J , Zee B , Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol . 1998;16(1):139–144.9440735
   PubMed Web of Science ®Google Scholar
• Cocks K , King MT , Velikova G , Martyn St-James M , Fayers PM , Brown JM . Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol . 2011;29(1):89–96.21098316
   PubMed Web of Science ®Google Scholar
• Pickard AS , Neary MP , Cella D . Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes . 2007;5:70.18154669
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration . Regorafenib Full Prescribing Information. 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf. Accessed 1 11, 2021.
   Google Scholar
• Bekaii-Saab TS , Ou FS , Ahn DH , et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol . 2019;20(8):1070–1082.31262657
   PubMed Web of Science ®Google Scholar
• Van cutsem E , Martinelli E , Cascinu S , et al. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study. Oncologist . 2019;24(2):185–192.30190299
   PubMed Web of Science ®Google Scholar